Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 2023 ANNA CE Symposium- Newer Therapies to Optimize Outcomes in Patients with Chronic Kidney Disease By: PRLog April 06, 2023 at 11:48 AM EDT This CE Symposium takes place during the 2023 American Nephrology Nurses Association #ANNAnurses on Tuesday, May 9, 2023 from 6:30 AM - 8:30 PM PT at the Palm Springs Convention Center, Palm Springs, California.HAZLET, N.J. - April 6, 2023 - PRLog -- In this CE Symposium, during the 2023 American Nephrology Nurses Association #ANNAnurses, expert faculty will discuss the clinical evidence that newer potassium binders and sodium-glucose cotransporter-2 (SGLT2) inhibitors can have a dramatic impact on outcomes of patients with chronic kidney disease (CKD). Potassium binders can not only effectively treat hyperkalemia, which can potentially be life-threatening, but very importantly enable CKD patients to continue taking life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Furthermore, potassium binders can prevent the need for urgent rescue therapy to reduce serum potassium in end-stage renal disease (ESRD) patients undergoing adequate dialysis. SGLT2 inhibitors have demonstrated significant reductions in the progression of CKD as well as in cardiovascular risk—in individuals with and without type 2 diabetes. It is therefore essential for nephrology nurses to not only be aware of the robust clinical data with these therapies but also play a critical role in the effective implementation of therapy, patient education, and adherence. Therefore, in this symposium, experts will interpret clinical evidence with these agents, and panel discussions will address prudent patient behaviors and fundamental knowledge for outcomes to be optimized.Click here for more informationFACULTYMolly Cahill, APRN, BC, NP-C, CNNKansas City Kidney Consultants PaKansas City, MissouriDebra Castner, RN, MSN, APN, CNNNephrology Nursing ConsultantExmore, VirginiaDavid Cherney, MD CM, PhD, FRCP(C)Professor of Medicine, University of TorontoClinician Scientist, Division of Nephrology, UHNDirector, Renal Physiology Laboratory, UHNSenior Scientist, Toronto General Hospital Research InstituteToronto, Ontario, CanadaCsaba P. Kovesdy, MDFred Hatch Professor of MedicineDirector, Clinical Outcomes and Clinical Trials Program in NephrologyUniversity of Tennessee Health Science CenterMemphis VA Medical CenterMemphis, TennesseeVoxmedia LLC gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.This educational activity is intended for nephrology nurses and other nurses and clinicians treating patients with #hyperkalemia.American Nephrology Nurses Association (ANNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.ANNA is a provider by the California Board of Registered Nursing, provider number CEP 00910.Pre-registration is for planning purposes only and does not guarantee seating. For additional CME/CE activities visit www.CMEPlanet.com #ANNAnurses #sglt2 #nephrology #nephrologynurse #hyperkalemiaContactVoxmedia***@voxmedia.usPhotos: (Click photo to enlarge) Read Full Story - 2023 ANNA CE Symposium- Newer Therapies to Optimize Outcomes in Patients with Chronic Kidney Disease | More news from this sourcePress release distribution by PRLog Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
2023 ANNA CE Symposium- Newer Therapies to Optimize Outcomes in Patients with Chronic Kidney Disease By: PRLog April 06, 2023 at 11:48 AM EDT This CE Symposium takes place during the 2023 American Nephrology Nurses Association #ANNAnurses on Tuesday, May 9, 2023 from 6:30 AM - 8:30 PM PT at the Palm Springs Convention Center, Palm Springs, California.HAZLET, N.J. - April 6, 2023 - PRLog -- In this CE Symposium, during the 2023 American Nephrology Nurses Association #ANNAnurses, expert faculty will discuss the clinical evidence that newer potassium binders and sodium-glucose cotransporter-2 (SGLT2) inhibitors can have a dramatic impact on outcomes of patients with chronic kidney disease (CKD). Potassium binders can not only effectively treat hyperkalemia, which can potentially be life-threatening, but very importantly enable CKD patients to continue taking life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Furthermore, potassium binders can prevent the need for urgent rescue therapy to reduce serum potassium in end-stage renal disease (ESRD) patients undergoing adequate dialysis. SGLT2 inhibitors have demonstrated significant reductions in the progression of CKD as well as in cardiovascular risk—in individuals with and without type 2 diabetes. It is therefore essential for nephrology nurses to not only be aware of the robust clinical data with these therapies but also play a critical role in the effective implementation of therapy, patient education, and adherence. Therefore, in this symposium, experts will interpret clinical evidence with these agents, and panel discussions will address prudent patient behaviors and fundamental knowledge for outcomes to be optimized.Click here for more informationFACULTYMolly Cahill, APRN, BC, NP-C, CNNKansas City Kidney Consultants PaKansas City, MissouriDebra Castner, RN, MSN, APN, CNNNephrology Nursing ConsultantExmore, VirginiaDavid Cherney, MD CM, PhD, FRCP(C)Professor of Medicine, University of TorontoClinician Scientist, Division of Nephrology, UHNDirector, Renal Physiology Laboratory, UHNSenior Scientist, Toronto General Hospital Research InstituteToronto, Ontario, CanadaCsaba P. Kovesdy, MDFred Hatch Professor of MedicineDirector, Clinical Outcomes and Clinical Trials Program in NephrologyUniversity of Tennessee Health Science CenterMemphis VA Medical CenterMemphis, TennesseeVoxmedia LLC gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.This educational activity is intended for nephrology nurses and other nurses and clinicians treating patients with #hyperkalemia.American Nephrology Nurses Association (ANNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.ANNA is a provider by the California Board of Registered Nursing, provider number CEP 00910.Pre-registration is for planning purposes only and does not guarantee seating. For additional CME/CE activities visit www.CMEPlanet.com #ANNAnurses #sglt2 #nephrology #nephrologynurse #hyperkalemiaContactVoxmedia***@voxmedia.usPhotos: (Click photo to enlarge) Read Full Story - 2023 ANNA CE Symposium- Newer Therapies to Optimize Outcomes in Patients with Chronic Kidney Disease | More news from this sourcePress release distribution by PRLog